Which types of tumors are Tepotinib (Tuodekang) mainly effective for?

Tepotinib (Tepotinib) is an oral small molecule METtyrosine kinase inhibitor that mainly targets MET exons Patients with non-small cell lung cancer (NSCLC) with skip mutations in pan>14 (METex14). By inhibiting the MET signaling pathway, tepotinib can block tumor cell proliferation and migration signals, thereby delaying tumor progression. As a precision targeted drug, it shows significant efficacy in people with specific gene mutations and is an important choice for the treatment of MET-driven lung cancer.

Tepotinib is mainly used to treat patients with advanced or metastatic non-small cell lung cancer, especially patients with MET exon 14 skipping mutations. Such mutations are often associated with rapid tumor progression and poor prognosis, so targeted therapy has important clinical value. Except for small cell lung cancer or other types of tumors, the current main indications for Tepotinib are still METex14-positive NSCLC.

In clinical trials, tepotinib showed good anti-tumor activity and tolerability. For METex14 mutation-positive patients, tepotinib can significantly improve progression-free survival (PFS) and objective response rate (ORR) regardless of whether they have received chemotherapy. In addition, oral administration facilitates long-term maintenance treatment for patients, while side effects are controllable in most patients, mainly manifesting as edema, muscle pain and mild gastrointestinal discomfort.

The use of tepotinib needs to be based on genetic testing results to ensure that the patient carries the METex14 skipping mutation. When making selections, doctors will develop an individualized dosage plan based on the patient's previous treatment history, tumor stage and overall health status. For advanced patients who are not suitable for chemotherapy or who want targeted therapy, tepotinib provides an effective and safe treatment option. At the same time, the efficacy and adverse reactions need to be closely monitored during the medication process to optimize treatment management.

Reference link:https://www.drugs.com